NCT00144482已完成3 期
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 122
- 主要终点
- The increase in Hb concentration
研究概览
简要总结
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 79 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cancer patients
排除标准
- •a history of myocardial, cerebral or pulmonary infarction
- •severe hypertension beyond control by drugs
研究组 & 干预措施
1
Experimental
干预措施: recombinant human erythropoietin (Drug)
2
Placebo Comparator
干预措施: recombinant human erythropoietin placebo (Drug)
结局指标
主要结局
The increase in Hb concentration
时间窗: week 8
次要结局
- Changes in QOL scores(8 weeks)
研究者
相似试验
Unknown
3 期
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）Age Related Macular DegenerationNCT04572698Luye Pharma Group Ltd.416
已完成
3 期
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian AncestryAsthmaNCT01498653GlaxoSmithKline313
已完成
不适用
Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral PalsyCerebral PalsyNCT01193660Sung Kwang Medical Foundation105
已完成
1 期
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VIMucopolysaccharidosis VINCT00048620BioMarin Pharmaceutical
终止
3 期
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®MelanomaNCT06587451Sandoz52